数据链接：
官方服务：
资源简介：
Treatment emergent adverse events (AEs).
应用场景：
创建时间：
2020-01-27
相关数据集
Selected tracts of the 862 cases of upper gastrointestinal complications and 15,505 matched controls.
†Measured over the 30-day period prior the index date. ‡Measured over the 60-day period prior the index date. Hospital admissions considered in this count does not include hospitalization for UGIC. *A
NIAID Data Ecosystem70
Adverse Event Dataset in Multiple Dose Pharmacokinetic Study of Meropenem in Young Infants (<91 days) with Suspected or Complicated Intra-abdominal Infections
Timing and description of adverse events Study Description An open-label, multiple-dose study to determine the safety, tolerability, and pharmacokinetics of meropenem in preterm and term infants less
NIAID Data Ecosystem20
Neoadjuvant nivolumab or nivolumab plus ipilimumab in early triple negative breast cancer with tumor infiltrating lymphocytes: the phase II BELLINI trial
Adverse events observed in BELLINI phase II trial
Figshare2024-09-17 更新20
Frequency of different grades of transaminase elevations and total bilirubin elevations according to study group.
Frequency of different grades of transaminase elevations and total bilirubin elevations according to study group.
NIAID Data Ecosystem20
Adverse events in all cycles of treatment for all patients receiving at least one cycle of treatment in the CSV and MSV groups.
Adverse events in all cycles of treatment for all patients receiving at least one cycle of treatment in the CSV and MSV groups.
NIAID Data Ecosystem20
